ONO PHARMACEUTICAL (4528) FY2027 Q1 Earnings Report

Quick View

Executive Summary

The first quarter was characterized by lower revenue but higher earnings, with Operating Income and Net Income increasing significantly as a result of improved gross margin and cost controls. Revenue was ¥116.16B (¥127.54B in the previous year, YoY -8.9%), Operating Income was ¥30.65B (¥21.99B in the previous year, YoY +39.4%), Profit Before Tax was ¥31.25B (+38.0%), and quarterly Net Income attributable to owners of the parent was ¥24.15B (¥17.67B in the previous year, YoY +36.7%). The primary drivers of the earnings increase were the improvement in gross margin resulting from a reduction in cost of sales (75.3%, up +4.3pt year on year) and greater cost-structure efficiency resulting from absolute declines in SG&A expenses and R&D expenses.

Factors Affecting Business Performance

【Revenue】Revenue was ¥116.16B, representing a YoY decline of -8.9%. As the Company operates a single segment, the Pharmaceutical Business, it does not disclose the factors behind changes by business. However, cost of sales also declined substantially to ¥28.68B (-22.5% year on year), suggesting that changes in product mix affected both revenue and earnings.

【Profit and Loss】Gross profit was ¥87.48B, and the gross margin of 75.3% improved by +4.3pt from 70.98% in the previous year. SG&A expenses declined to ¥23.90B (-23.1%), while R&D expenses decreased to ¥32.40B (-10.6%, 27.9% of revenue). As a result, Operating Income increased to ¥30.65B (+39.4%), and the Operating Margin expanded to 26.4%, up +9.2pt from 17.2% in the previous year. Financial income of ¥1.38B and financial expenses of ¥0.78B were broadly in line with the previous year and had a limited impact on earnings. Profit Before Tax was ¥31.25B (+38.0%), and quarterly Net Income attributable to owners of the parent was ¥24.15B (+36.7%). In conclusion, the current period delivered lower revenue but higher earnings.

Key Financial Indicators

【Profitability】The Operating Margin was 26.4%, improving by +9.2pt from 17.2% in the previous year, while the Net Profit Margin, based on income attributable to owners of the parent, was 20.8%, up +6.9pt from 13.9% in the previous year. The increase in gross margin to 75.3% (71.0% in the previous year), together with reductions in SG&A and R&D expenses, were the two main drivers of improved profitability. 【Cash Flow Quality】Operating Cash Flow (OCF) was only ¥1.05B, and its ratio to Net Income attributable to owners of the parent of ¥24.15B was just 0.04x. 【Investment Efficiency】ROE, calculated as quarterly income attributable to owners of the parent divided by average equity during the period on a quarterly basis, was 2.8%, a slight increase from 2.3% in the same period of the previous year. Total assets were ¥1,084.41B, slightly down from ¥1,065.15B in the previous year, and total asset turnover remained low. 【Financial Soundness】The Equity Ratio was 79.9%, up +3.0pt from 76.9% in the previous year, while cash and cash equivalents stood at ¥219.54B. Current assets of ¥436.55B compared with current liabilities of ¥132.96B resulted in a current ratio of approximately 3.3x, indicating a strong liquidity position.

Cash Flow Analysis

Operating Cash Flow was ¥1.05B, down -68.8% from ¥3.37B in the previous year, and was substantially below Net Income attributable to owners of the parent of ¥24.15B. The primary factors were a sharp increase in income taxes paid to ¥30.24B (¥4.05B in the previous year) and a ¥13.04B decrease in trade and other payables, which weakened working capital. Investing Cash Flow turned positive at ¥3.42B (¥-43.04B in the previous year). In addition to the reversal of the previous year's ¥45.79B investment in the acquisition of intangible assets, proceeds of ¥8.40B from the sale of intangible assets contributed in the current period. Financing Cash Flow was ¥-21.85B, with dividend payments of ¥17.47B and repayment of long-term borrowings of ¥7.50B as the main cash outflows. Free Cash Flow was ¥4.48B, remaining below dividend payments. Cash and cash equivalents decreased by ¥17.50B from ¥237.05B at the beginning of the period to ¥219.54B at the end of the period.

Earnings Quality

The earnings increase in the current period was led by operating activities. Financial income of ¥1.38B and financial expenses of ¥0.78B each represented approximately 1% of revenue, and no temporary items equivalent to extraordinary gains or losses were identified. The bridge from Profit Before Tax of ¥31.25B to Net Income attributable to owners of the parent of ¥24.15B, after deducting income taxes of ¥7.09B (effective tax rate of 22.7%), was at a standard level. However, OCF of ¥1.05B was substantially below Net Income attributable to owners of the parent, resulting in a ratio of 0.04x. The expansion of accruals due to concentrated income tax payments and a decrease in trade payables should be noted when assessing earnings quality. Comprehensive income was ¥34.89B, ¥10.73B above consolidated quarterly income of ¥24.16B. Increases in other comprehensive income, including foreign currency translation adjustments for foreign operations (+¥4.97B, compared with -¥10.51B in the previous year) and changes in the fair value of financial assets (+¥5.79B), boosted equity.

Earnings Forecasts and Guidance

Progress against the full-year company plan of Revenue of ¥455.00B, Operating Income of ¥94.00B, and Net Income of ¥71.00B was 25.5% for Revenue, 32.6% for Operating Income, and 34.0% for Net Income attributable to owners of the parent. Progress for Operating Income and Net Income exceeded the simple progress benchmark of 25% by more than 7pt, indicating that the effects of gross-margin improvement and cost controls are emerging ahead of plan. The Company made no revisions to either its earnings forecast or dividend forecast during the quarter.

Shareholder Returns

The Company's full-year dividend forecast is ¥80 (forecast EPS of ¥151.09), implying a Payout Ratio of approximately 53.0%. Share repurchases during Q1 were negligible, with cash outflows from purchases effectively zero; shareholder returns therefore primarily consisted of dividends. Dividend payments were ¥17.47B, exceeding Q1 Free Cash Flow of ¥4.48B. However, given the financial base of cash and cash equivalents of ¥219.54B and an Equity Ratio of 79.9%, full-year coverage will depend on available cash and the recovery of OCF.

Risk Factors

1. Pipeline and patent-related risks: R&D expenses remained high at ¥32.40B (27.9% of revenue, slightly down from 28.4% in the previous year). The YoY decline of -8.9% in current-period Revenue appears to reflect changes in sales trends for existing products. Changes in product mix resulting from patent expirations and generic-drug entry remain areas requiring continuous monitoring.

2. Temporary decline in cash conversion: OCF was ¥1.05B, with a ratio of 0.04x to Net Income attributable to owners of the parent of ¥24.15B. The primary factors were concentrated income tax payments of ¥30.24B and a ¥13.04B decrease in trade payables, suggesting fluctuations attributable to tax and working-capital timing.

3. Foreign exchange and fluctuations in other comprehensive income: Foreign currency translation adjustments for foreign operations were +¥4.97B in the current period, compared with -¥10.51B in the previous year, indicating a structure in which exchange-rate fluctuations affect equity levels through comprehensive income and other equity components.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Returns

Both the Operating Margin and Net Profit Margin were substantially above the industry median, placing the Company's profitability at a high level within the industry.

Growth and Capital Efficiency

The Revenue Growth Rate was substantially below the industry median, placing the Company at a disadvantage within the industry in terms of top-line growth.

※Source: Compiled by the Company

Key Takeaways from the Earnings Results

1. Despite lower revenue, the Gross Margin improved by +4.3pt and reductions in SG&A and R&D expenses expanded the Operating Margin from 17.2% to 26.4%. Greater cost-structure efficiency was the primary driver of the earnings increase in the current period.

2. Progress for profit against the full-year plan—32.6% for Operating Income and 34.0% for Net Income—exceeded Revenue progress of 25.5%, indicating that improvements in gross margin and costs are emerging ahead of plan.

3. OCF was only 0.04x Net Income attributable to owners of the parent. Due to concentrated income tax payments and working-capital movements, cash generation in Q1 did not keep pace with the increase in earnings.

Theoretical Share Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson-type model with an explicit five-year fade period). It is not a forecast of the market share price or a recommendation to take any specific investment action.

Sensitivity: ¥1,781–¥1,883 at ±1% for the Cost of Equity, and ¥1,830–¥1,831 at ±0.1 for ω.

Notes:

• Since forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net assets as of the end of the quarter are used, resulting in a timing mismatch with the full-year forecast.

(Calculation model: Residual Income Model / Interest rate reference month: 2026-06 / This value does not predict or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings-release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional adviser as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a strong profit-delivery quarter despite an 8.9% year-on-year revenue decline. Revenue was JPY116.2bn, while operating income rose 39.4% year on year to JPY30.7bn and profit attributable to owners rose 36.7% to JPY24.2bn. The earnings outcome was driven primarily by a substantial reduction in cost of sales and disciplined operating expenditure rather than top-line growth. Gross profit declined only 3.4% to JPY87.5bn, materially less than the revenue decline. Accordingly, gross margin expanded to 75.3% from 71.0% a year earlier, a 430bp improvement. SG&A expense fell 23.1% to JPY23.9bn, reducing its revenue ratio to 20.6% from 24.4%. R&D expense declined 10.6% to JPY32.4bn, although R&D intensity remained high at 27.9% of revenue. Operating margin expanded sharply to 26.4% from 17.2%, an approximately 914bp improvement. Net profit margin similarly expanded to 20.8% from 13.8%, or roughly 697bp. Finance income of JPY1.4bn exceeded finance costs of JPY0.8bn, supporting pre-tax profit, although the contribution was modest relative to operating income. The effective tax rate was 22.7%, producing a normal tax burden factor of 0.773. Reported annualized ROE was 11.1%, which is solid but remains below the 15% level generally associated with excellent profitability. Cash conversion was the principal weakness: operating cash flow was only JPY1.1bn, equivalent to 0.04x net income, because JPY30.2bn of income-tax payments absorbed cash. Free cash flow of JPY4.5bn was positive only because investing cash flow included JPY8.4bn of proceeds from intangible-asset sales; recurring operating cash generation after tangible capex was negative. The balance sheet remains highly resilient, with a 79.9% equity ratio, JPY219.5bn of cash and JPY106.9bn of interest-bearing debt. Management maintained full-year guidance, and Q1 progress was ahead of a linear quarterly pace for operating profit and net income. The forward issue is whether cost-of-sales savings and lower SG&A can offset continued revenue pressure while the company sustains a high level of R&D investment and manages its sizeable intangible-asset base.

Profitability Analysis

The annualized DuPont decomposition is net profit margin of 20.8% × asset turnover of 0.428x × financial leverage of 1.24x, resulting in reported annualized ROE of 11.1%. The largest positive driver was margin expansion, not leverage: operating margin improved by approximately 914bp year on year to 26.4%, while net margin rose approximately 697bp to 20.8%. Gross-margin expansion of 430bp reflects cost of sales falling 22.5%, substantially faster than the 8.9% revenue decline. Operating leverage was strongly favorable because SG&A fell 23.1% and R&D fell 10.6%, reducing the combined SG&A-plus-R&D burden to 48.5% of revenue from 52.8% a year earlier. The high R&D intensity of 27.9% remains above the 15-20% innovator-pharma benchmark and indicates that the earnings improvement was achieved while maintaining substantial pipeline investment. Financial leverage is conservative at 1.24x and debt-to-equity is 0.24x, so the return profile is fundamentally operating-driven rather than debt-amplified. The 1.019 interest-burden factor confirms that finance income modestly exceeded finance costs, while the 0.773 tax-burden factor indicates a normal effective tax rate. Annualized asset turnover of 0.428x is modest, consistent with a pharmaceutical business carrying a large intangible-asset base. The sustainability of the Q1 margin step-up depends on whether lower cost of sales and SG&A represent durable mix and efficiency benefits rather than timing effects. Revenue contraction remains the central constraint on sustained ROE expansion.

Growth Assessment

Top-line momentum was negative in Q1, with revenue down JPY11.4bn year on year to JPY116.2bn. However, gross profit declined by only JPY3.0bn, demonstrating significantly improved revenue-to-gross-profit conversion. Operating income increased by JPY8.7bn and net income increased by JPY6.5bn, indicating that profit growth was materially decoupled from sales growth in the quarter. Q1 R&D expense of JPY32.4bn equates to 27.9% of revenue, above the industry innovator-pharma benchmark and supportive of long-term product and pipeline renewal, although it increases the need for productive commercialization outcomes. Full-year guidance calls for revenue of JPY455.0bn, operating income of JPY94.0bn and net income of JPY71.0bn. Q1 progress against full-year guidance was 25.5% for revenue, 32.6% for operating income and 34.0% for net income. Revenue progress is broadly in line with the standard 25% Q1 run-rate, while operating-profit and net-income progress are ahead by 7.6ppt and 9.0ppt, respectively, but not more than the 10ppt threshold for a formal pace deviation. The unchanged forecast implies management has not yet treated the Q1 margin outperformance as fully recurring. With a single pharmaceutical segment, group-level growth is dependent on the portfolio's ability to counter price, reimbursement, competition and lifecycle pressures. The Q1 decline in R&D spending should be monitored alongside clinical progress and commercialization needs, as a lower expense level is positive for near-term earnings but should not weaken the innovation base.

Financial Health

Financial health is strong. Current assets of JPY436.6bn exceeded current liabilities of JPY133.0bn, implying a current ratio of approximately 3.3x and positive working capital of approximately JPY303.6bn. Cash and cash equivalents were JPY219.5bn, equal to approximately 5.6x short-term borrowings of JPY39.4bn, providing ample coverage of near-term debt. The reported liquidity-stress alert showing cash-to-short-term-debt of 0.00x is not supported by the disclosed balance-sheet amounts; the disclosed cash balance materially exceeds short-term borrowings. Total interest-bearing debt was JPY106.9bn against total equity of JPY872.7bn, equivalent to debt-to-equity of 0.24x and debt-to-capital of 10.9%. These leverage levels are conservative and well inside investment-grade reference levels. Short-term debt accounts for 36.9% of total interest-bearing debt, but there is no material maturity mismatch because cash alone is substantially greater than short-term debt and current assets are more than three times current liabilities. Long-term borrowings decreased by JPY7.5bn from fiscal year-end, partly offset by a JPY4.0bn increase in short-term borrowings. Total liabilities fell JPY38.2bn from fiscal year-end, principally reflecting lower income taxes payable and trade payables. The capital base increased JPY16.1bn to JPY872.7bn despite JPY18.8bn of owner distributions, supported by Q1 earnings and JPY10.7bn of other comprehensive income. Intangible assets represent 32.7% of total assets, above the 30% concentration alert threshold, making future asset values and impairment testing important to the balance-sheet assessment. Goodwill is limited at 2.6% of equity and 2.1% of assets, so goodwill-related acquisition risk is low relative to the broader intangible-asset exposure. Lease liabilities total JPY10.2bn and are modest relative to equity and liquidity.

Notable B/S Changes

Income taxes payable: -JPY21.7bn (-70.6%) from FY-end to JPY9.0bn, consistent with the JPY30.2bn Q1 cash tax payment and the weak operating-cash-flow conversion. Trade and other payables: -JPY13.6bn (-21.6%) to JPY49.4bn, representing a material working-capital cash outflow during the quarter. Other current financial liabilities: +JPY2.6bn (+180.0%) to JPY4.1bn; the increase is small relative to total assets but warrants monitoring given the percentage movement. Investment securities: +JPY9.4bn (+10.0%) to JPY102.6bn, alongside JPY5.8bn of fair-value gains recognized in equity OCI; this increased non-operating market-value exposure modestly. Other components of equity: +JPY10.8bn (+22.2%) to JPY59.5bn, principally reflecting positive OCI from equity-security fair-value gains and foreign-currency translation gains.

Cash Flow Quality

Cash-flow quality was weak in Q1 despite strong accounting earnings. Operating cash flow was JPY1.1bn versus net income of JPY24.2bn, resulting in an OCF/net-income ratio of 0.04x, well below the 0.8x warning threshold. The root cause was primarily JPY30.2bn of income-tax payments, which almost fully offset the JPY30.7bn pre-tax operating cash-flow subtotal. This payment timing is a cash-flow burden rather than evidence that the reported income itself is unsupported, but it materially limits near-term distributable cash generation. Working-capital movements were mixed: receivables generated JPY5.4bn of cash and inventories generated JPY2.0bn, while trade and other payables used JPY13.0bn. The receivables and inventory movements do not indicate a Q1 build-up of working capital to support reported earnings. However, inventory days were 177 days on an annualized cost-of-sales basis, above both the 90-day and 60-day alert thresholds. The elevated inventory level is a pharmaceutical-specific monitoring issue because it can reflect supply-chain buffers, product-launch positioning, slower sell-through or eventual obsolescence risk; its impact is presently mitigated by inventories declining JPY1.7bn from fiscal year-end. Reported free cash flow was positive JPY4.5bn, but it was supported by JPY8.4bn of proceeds from intangible-asset sales and should not be viewed as wholly recurring operating free cash flow. Operating cash flow less tangible capex was negative JPY0.9bn, and it was more negative after JPY3.6bn of intangible-asset purchases. The low 2.1% accruals ratio is otherwise favorable and does not indicate unusually aggressive earnings accruals. Cash fell JPY17.5bn in Q1 after dividends, debt repayment and operating tax payments, but the closing cash balance of JPY219.5bn remains substantial.

Dividend Sustainability

The disclosed full-year dividend forecast is JPY80 per share and has not been revised. Against forecast EPS of JPY151.09, the implied dividend payout ratio is approximately 53.0%, within the sub-60% sustainability benchmark. There were no material share buybacks in Q1, so the assessment is appropriately based on the dividend payout ratio rather than a total return ratio. Cash dividends paid in Q1 were JPY17.5bn, broadly matching the prior-year payment level. Q1 operating cash flow of JPY1.1bn did not cover the cash dividend because of the exceptional scale of tax payments during the quarter. Reported free cash flow of JPY4.5bn also did not cover the Q1 dividend, and it benefited from proceeds on intangible-asset sales. Nevertheless, the dividend is supported by JPY219.5bn of cash, conservative 0.24x debt-to-equity and a large retained-earnings balance of JPY835.4bn. Dividend sustainability over the full year therefore depends more on normalization of operating cash conversion and delivery of the JPY71.0bn net-income forecast than on near-term balance-sheet capacity. A durable deterioration in operating cash flow, or further revenue erosion that reduces earnings below guidance, would be the principal factors that could constrain future distribution flexibility.

Risk Assessment

Business risks include Revenue declined 8.9% year on year; sustained sales pressure could ultimately overwhelm the Q1 cost and margin improvements., Pharmaceutical lifecycle risk remains material, including generic and branded competition, reimbursement and drug-pricing reform, regulatory outcomes, and product-demand volatility., R&D intensity was 27.9% of revenue. This supports innovation but creates execution risk if clinical development, approvals or commercialization fail to generate adequate returns., Inventory days of 177 are elevated for the stated cost base. While inventory declined from fiscal year-end, continued monitoring is warranted for demand forecasting, expiry and obsolescence exposure..

Financial risks include OCF/net income of 0.04x is materially below the quality threshold because JPY30.2bn of tax payments constrained cash conversion; recurrence of such cash outflows would weaken internally funded dividends and investment., Intangible assets account for 32.7% of total assets, above the 30% concentration threshold. Future impairment or weaker-than-expected asset cash flows could affect earnings and capital., Q1 reported free cash flow relied on JPY8.4bn of proceeds from intangible-asset sales, reducing the comparability of the positive JPY4.5bn headline FCF figure..

Key concerns include Highest priority: determine whether the 914bp operating-margin expansion can persist while revenue is contracting., High priority: monitor quarterly operating cash flow after tax payments, the sustainability of dividend funding, and the normalization of cash conversion., High priority: monitor inventory days and the composition, useful lives and impairment testing of the JPY355.0bn intangible-asset balance., Moderate priority: track progress versus unchanged FY2027 guidance, especially whether Q1 operating-profit progress of 32.6% remains supported in subsequent quarters., Balance-sheet leverage and near-term liquidity are low-priority risks given the 3.3x current ratio, JPY219.5bn cash balance and 0.24x debt-to-equity..

Investment Implications

Key takeaways include Q1 profitability materially outperformed the revenue trend: operating income rose 39.4% despite an 8.9% sales decline., Gross-margin expansion, lower SG&A and a modest reduction in R&D spending were the principal drivers of the earnings increase., The company has a strong capital structure, with a 79.9% equity ratio, debt-to-equity of 0.24x and cash exceeding short-term borrowings by approximately 5.6x., Cash earnings conversion is the key counterweight to the strong P&L outcome, as OCF was only JPY1.1bn and 0.04x net income., The implied FY2027 dividend payout ratio of approximately 53% is reasonable relative to forecast earnings, although Q1 cash flow did not cover distributions..

Metrics to watch include Revenue trajectory and the durability of the 26.4% operating margin, Cost of sales as a percentage of revenue and SG&A-to-revenue ratio, R&D intensity and evidence of pipeline and commercialization productivity, Operating cash flow, cash taxes paid and OCF/net-income conversion, Inventory days, inventory turnover and potential obsolescence indicators, Intangible-asset additions, disposals, impairment charges and impairment assumptions, FY2027 progress versus JPY455.0bn revenue, JPY94.0bn operating income and JPY71.0bn net income guidance.

Regarding relative positioning, The company combines an excellent 75.3% gross margin, a 26.4% operating margin, solid annualized ROE of 11.1% and a very conservative balance sheet. Relative to typical innovator-pharma characteristics, its R&D intensity is high and supports long-term innovation capacity, while the 32.7% intangible-asset concentration and weak Q1 cash conversion require closer scrutiny. The central analytical balance is strong current profitability and financial resilience versus sales contraction, tax-driven cash-flow weakness and the execution burden inherent in a research-intensive pharmaceutical portfolio.